Huskey S E, Miller R R, Chiu S H
Department of Animal and Exploratory Drug Metabolism, Merck Research Laboratories, Rahway, NJ 07065.
Drug Metab Dispos. 1993 Sep-Oct;21(5):792-9.
In vitro conditions for the preparation of tetrazole N2-glucuronides using liver microsomes (enriched with UDP-glucuronic acid) from rats, dogs, monkeys, and humans have been developed and optimized. The structures of tetrazole N2-glucuronides of 3 biphenyl tetrazole-containing angiotensin II (AII) receptor antagonists MK-954 (I), L-158,338 (II), and L-158,809 (III), and a model compound methyl biphenyl tetrazole (IV) were determined either by NMR and mass spectrometry or by comparison of HPLC retention times with that from authentic compounds. The species difference as well as gender difference in the rate of the in vitro reaction were compared. The optimal pH for the reaction was determined to be 5.0 with liver microsomes from monkeys and humans, and 6.2 with those from rats and dogs. For the model compound IV, the rate of N2-glucuronidation by liver microsomes from rats, dogs, and monkeys was approximately 10-fold faster than that by humans. For the AII receptor antagonists I, II, and III, the rate of the same reaction by liver microsomes from dogs and monkeys was much faster than that by humans. The relative intrinsic rate of this reaction for these three substrates ranked similarly in rats and humans as II > III > I. With compound I, a biphenyl tetrazole-containing imidazole derivative that has potential sites for both O- (primary hydroxyl) and N2-(tetrazole) glucuronidation, both O- and tetrazole N2-glucuronides were formed by liver microsomes from rats and monkeys (at neutral pH), whereas N2-glucuronide was the only product from dogs and humans.(ABSTRACT TRUNCATED AT 250 WORDS)
已开发并优化了使用大鼠、狗、猴子和人类肝脏微粒体(富含尿苷二磷酸葡萄糖醛酸)制备四氮唑N2 - 葡萄糖醛酸苷的体外条件。通过核磁共振和质谱法,或通过将高效液相色谱保留时间与真实化合物的保留时间进行比较,确定了3种含联苯四氮唑的血管紧张素II(AII)受体拮抗剂MK - 954(I)、L - 158,338(II)和L - 158,809(III)以及模型化合物甲基联苯四氮唑(IV)的四氮唑N2 - 葡萄糖醛酸苷的结构。比较了体外反应速率的物种差异以及性别差异。确定猴子和人类肝脏微粒体反应的最佳pH为5.0,大鼠和狗的为6.2。对于模型化合物IV,大鼠、狗和猴子肝脏微粒体的N2 - 葡萄糖醛酸化速率比人类快约10倍。对于AII受体拮抗剂I、II和III,狗和猴子肝脏微粒体的相同反应速率比人类快得多。这三种底物在大鼠和人类中该反应的相对内在速率排序相似,为II > III > I。化合物I是一种含联苯四氮唑的咪唑衍生物,具有O - (伯羟基)和N2 - (四氮唑)葡萄糖醛酸化的潜在位点,大鼠和猴子的肝脏微粒体(在中性pH下)会形成O - 和四氮唑N2 - 葡萄糖醛酸苷,而狗和人类的产物只有N2 - 葡萄糖醛酸苷。(摘要截断于250字)